Compare INDI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | RGNX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.6M | 793.5M |
| IPO Year | 2021 | 2015 |
| Metric | INDI | RGNX |
|---|---|---|
| Price | $1.59 | $6.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $5.28 | ★ $23.58 |
| AVG Volume (30 Days) | ★ 5.5M | 1.3M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.95 | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,394,000.00 | $10,393,000.00 |
| Revenue This Year | $22.61 | N/A |
| Revenue Next Year | $33.22 | $23.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.33 | ★ 126.48 |
| 52 Week Low | $1.54 | $5.46 |
| 52 Week High | $5.97 | $16.19 |
| Indicator | INDI | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 16.04 | 34.87 |
| Support Level | N/A | $5.67 |
| Resistance Level | $3.32 | $7.32 |
| Average True Range (ATR) | 0.14 | 0.46 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 6.64 | 2.73 |
Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.